Poor
Not Aligned
Patient Risk:
High
Summary
Mixed alignment: some pharmacology/cardiovascular endpoint wording is broadly consistent, but multiple alcohol/wine, grapefruit/bleeding, resveratrol, and wine–warfarin interaction claims are not supported by the provided labeling sections and introduce potentially misleading safety implications.
Category Scores
Accurate Statements
Lipitor (atorvastatin) works by inhibiting the production of cholesterol in the liver.
Supported by 12.1 (HMG-CoA reductase inhibition and cholesterol synthesis inhibition in the liver).
By reducing cholesterol produced in the liver, Lipitor lowers low-density lipoprotein (LDL) cholesterol in the blood.
Supported by 12.1 (reduces LDL production/LDL particles; lowers LDL-C).
Lipitor can cause muscle damage in some people.
Partially supported by 5.1 (myopathy/rhabdomyolysis described as adverse effects).
Lipitor helps to reduce the risk of heart disease and stroke.
Partially supported by 1.1 (reduces myocardial infarction and stroke; wording is broader than label endpoints).
If a person has pre-existing liver disease, their doctor may recommend regular liver function tests to monitor for signs of damage.
Partially supported by 5.2 and 17.2 (liver function tests recommended prior to and after initiation/dose changes and periodically; 5.2 discusses caution with history of liver disease).
Unsupported Statements
Regular consumption of wine while taking Lipitor can increase the risk of adverse effects.
Label section provided (5.2) addresses use with caution in patients who consume substantial quantities of alcohol; it does not support a general 'regular wine' risk statement.
Grapefruit and grapefruit juice have been shown to increase the risk of bleeding when taken with certain medications, including statins like Lipitor.
No provided label text supports grapefruit increasing bleeding risk.
Wine contains resveratrol.
No provided label text addresses wine constituents such as resveratrol.
Resveratrol may have a similar effect to grapefruit with respect to bleeding risk when taken with Lipitor.
No provided label text addresses resveratrol or any bleeding-risk comparison.
Wine can interact with blood thinners such as warfarin.
No provided label text describes wine–warfarin interactions.
Interaction between wine and blood thinners can increase the risk of bleeding and other adverse effects.
No provided label text supports wine–blood thinner interaction or associated bleeding risk.
Drinking wine while taking Lipitor may increase the risk of muscle damage.
No provided label text connects alcohol/wine consumption to increased myopathy/rhabdomyolysis risk.
The American Heart Association defines drinking wine in moderation as up to one drink per day for women and up to two drinks per day for men.
No provided label text includes any external organization definition or drink-count guidance.
Drinking wine in moderation is unlikely to cause problems for most people taking statins like Lipitor.
No provided label text offers reassurance about moderation/lack of risk.
Individuals who drink more than the recommended amount may be at increased risk of adverse effects.
Provided label text supports caution with 'substantial quantities of alcohol' but does not define a 'recommended amount' threshold.
The risk of muscle damage with Lipitor is increased when taken in high doses.
Provided label text emphasizes interaction/dose-context risks (e.g., certain coadministered drugs) and does not support a general high-dose relationship as stated in the claim.
Contradictions
Important Omissions
Specific FDA labeling precautions regarding grapefruit/warfarin (only grapefruit juice CYP3A4 interaction and that Lipitor had no clinically significant effect on prothrombin time with chronic warfarin are present in the provided label excerpts), which would be necessary to correctly frame interaction risks.
Importance:
Moderate
For liver monitoring, the label provides explicit timing (prior to and at 12 weeks after initiation and after dose increases; periodically thereafter) rather than an individualized 'doctor may recommend' statement tied to pre-existing liver disease.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Unlabeled/unsupported interaction and bleeding-risk claims (grapefruit bleeding risk; wine–warfarin bleeding risk; resveratrol linkage) could mislead risk assessment. Several alcohol-related claims are framed more generally/causally than the provided label supports (which specifies caution for substantial alcohol and liver disease contraindications/cautions).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple statements about wine, grapefruit/bleeding, resveratrol, and wine–warfarin interactions are not supported by the provided FDA label excerpts and include potentially misleading safety implications.
Suggested Improvement
Remove or rewrite all alcohol/wine, grapefruit/bleeding, resveratrol, and wine–warfarin interaction claims to match the provided labeling language (e.g., 5.2: caution with substantial alcohol and liver disease contraindication; 7.2 grapefruit juice: CYP3A4 inhibition and increased atorvastatin concentrations; 7.7: no clinically significant effect on prothrombin time with chronic warfarin).